# Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

> **NCT03296033** · PHASE4 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 122 (actual)

## Conditions studied

- Anticoagulants and Bleeding Disorders
- Surgery
- Regional Anesthesia Morbidity

## Interventions

- **DRUG:** Enoxaparin
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT03296033
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-24
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 122 (ACTUAL)
- **Why stopped:** enrollment proved to be a challenge due to the changing of the guidelines for bridging off the new anticoagulants that are being prescribed
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03296033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03296033, "Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03296033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*